| Literature DB >> 26251828 |
Feifei Yang1, Bingyan Zhang1, Jie Yu1, Lingyun Shao1, Pu Zhou1, Liping Zhu1, Shu Chen1, Wenhong Zhang1, Xinhua Weng1, Jiming Zhang1, Yuxian Huang1.
Abstract
Limited research has been conducted on healthcare-associated infective endocarditis (HAIE), although it is of increasing importance. The aim of this study is to compare the epidemiology, clinical characteristics, and prognosis of community-acquired IE (CA-IE) with HAIE and non-nosocomial healthcare-associated IE (NNHCA-IE). A retrospective, consecutive case-series analysis was organized and performed during the 20-year study period in Huashan Hospital, Shanghai, China. A total of 154 patients were enrolled, including 126 (81.8%) who had CA-IE and 28 (18.2%) who had HAIE, among whom 20 (71.4%) had non-nosocomial IE. Patients with HAIE compared to patients with CA-IE had poorer clinical conditions (Charlson comorbidity index ≥2: 35.7% vs. 15.1%, P = 0.012; immunosuppressive therapy: 21.4% vs. 4.0%, P = 0.005), underwent more prosthetic valve replacement (35.7% vs. 7.1%, P <0.001), had less streptococcus infection (16.7% vs. 51.1%, P = 0.007) but more atypical bacterial infection (50.0% vs. 21.1%, P = 0.017) and poorer outcomes (17.9% vs. 4.0%, P = 0.019). It is noteworthy that the results were quite similar between the comparison of patients with NNHCA-IE and those with CA-IE. Overall, in-hospital mortality was 6.5%. The IE acquisition site and low serum albumin levels (odds ratio (OR): 0.8; P = 0.04) were significantly associated with an increased risk of mortality. Nosocomial IE patients had an 8.3-fold and NNHCA-IE patients had 6.5-fold increase in the risk of mortality compared to CA-IE patients. In conclusion, HAIE and NNHCA-IE have important epidemiological and prognostic implications. Because NNHCA-IE usually occurs in patients residing in the community, it is suggested that these patients should be identified and treated by the community primary care clinical staff as early as possible.Entities:
Keywords: epidemiology; healthcare-associated infections; infective endocarditis; mortality; risk factors
Mesh:
Year: 2015 PMID: 26251828 PMCID: PMC4522613 DOI: 10.1038/emi.2015.38
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163
Figure 1A flow chart of patient enrollment according to the modified Duke criteria. IE, infective endocarditis; CA, community-acquired; NNHCA, non-nosocomial healthcare-associated.
Possible source of infection in 28 cases of healthcare-associated infective endocarditis
| NNHCA-IE | NO (%) of cases ( | Nosocomial IE | NO (%) of cases ( |
|---|---|---|---|
| 13 (65.0%) | 6 (75.0%) | ||
| Cardiac surgery | 5 | Cardiac surgery | 3 |
| Intestinal operation | 3 | Bone surgery | 1 |
| Pancreatic duct incision | 1 | Pneumonectomy | 1 |
| Pacemaker implantation | 1 | Reconstruction of urethral stenosis | 1 |
| Pneumonectomy | 1 | 2 (25.0%) | |
| Tonsillectomy | 1 | ||
| Retinal reattachment surgery | 1 | ||
| 2 (10.0%) | |||
| 4 (20.0%) | |||
| 1 (5.0%) |
IE, infective endocarditis; NNHCA, non-nosocomial healthcare-associated.
Demographic characteristics, predisposing factors, clinical and echocardiographic findings, complications and outcomes of patients with infective endocarditis
| HAIE | |||||||
|---|---|---|---|---|---|---|---|
| Total | NNHCA-IE | Nosocomial IE | |||||
| All
| CA-IE
| ||||||
| 118 (76.6%) | 98 (77.8%) | 20 (71.4%) | 16 (80.0%) | 4 (50.0%) | 0.473 | >0.999 | |
| 46 (32–57) | 47 (32–57) | 43.5 (36–56) | 44 (39–56) | 35.5 (30–53) | 0.605 | 0.955 | |
| 102 (66.2%) | 84 (66.7%) | 18 (64.3%) | 13 (65.0%) | 5 (62.5%) | 0.810 | 0.884 | |
| Prosthetic valve | 19 (12.3%) | 9 (7.1%) | 10 (35.7%) | 7 (35.0%) | 3 (37.5%) | <0.001 | 0.002 |
| Congenital heart disease | 31 (20.1%) | 30 (23.8%) | 1 (3.6%) | 1 (5.0%) | 0 (0.0%) | 0.016 | 0.076 |
| Rheumatic heart disease | 24 (16.9%) | 14 (11.1%) | 10 (35.7%) | 7 (35.0%) | 3 (37.5%) | 0.002 | 0.011 |
| Charlson comorbidity index≥2 | 29 (18.8%) | 19 (15.1%) | 10 (35.7%) | 7 (35.0%) | 3 (37.5%) | 0.012 | 0.053 |
| Diabetes mellitus | 8 (5.2%) | 5 (4.0%) | 3 (10.7%) | 3 (15.0%) | 0 (0.0%) | 0.159 | 0.079 |
| Malignancy | 7 (4.5%) | 4 (3.2%) | 3 (10.7%) | 3 (15.0%) | 0 (0.0%) | 0.113 | 0.054 |
| Immunosuppressive therapy | 11 (7.1%) | 5 (4.0%) | 6 (21.4%) | 2 (10.0%) | 4 (50.0%) | 0.005 | 0.245 |
| Fever ≥39.1°C | 80 (53.0%) | 64 (51.6%) | 16 (59.3%) | 13 (68.4%) | 3 (37.5%) | 0.471 | 0.171 |
| Heart murmur | 130 (84.4%) | 109 (86.5%) | 21 (75.0%) | 16 (80.0%) | 5 (62.5%) | 0.129 | 0.492 |
| Purpuric lesion | 40 (26.0%) | 33 (26.2%) | 7 (25.0%) | 5 (25.0%) | 2 (25.0%) | 0.897 | 0.910 |
| Mitral valve | 85 (55.2%) | 65 (51.6%) | 20 (71.4%) | 13 (65.0%) | 7 (87.5%) | 0.056 | 0.264 |
| Aortic valve | 57 (37.0%) | 52 (41.3%) | 5 (17.9%) | 3 (15.0%) | 2 (25.0%) | 0.020 | 0.026 |
| Tricuspid valve | 10 (6.5%) | 8 (6.3%) | 2 (7.1%) | 1 (5.0%) | 1 (12.5%) | >0.999 | >0.999 |
| Vegetation | 134 (87.0%) | 110 (87.3%) | 24 (85.7%) | 16 (80.0%) | 8 (100%) | 0.051 | 0.480 |
| 96 (62.3%) | 80 (63.5%) | 16 (57.1%) | 12 (60.0%) | 4 (50.0%) | 0.393 | 0.764 | |
| Stroke | 22 (14.3%) | 16 (12.7%) | 6 (21.4%) | 4 (20.0%) | 2 (25.0%) | 0.240 | 0.480 |
| Brain abscess | 7 (4.5%) | 7 (5.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 0.594 |
| Acute left heart failure | 11 (7.1%) | 6 (4.8%) | 5 (17.9%) | 2 (10.0%) | 3 (37.5%) | 0.029 | 0.301 |
| Non-CNS embolism | 10 (6.5%) | 10 (7.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | 0.358 |
| In-hospital mortality | 10 (6.5%) | 5 (4.0%) | 5 (17.9%) | 3 (15.0%) | 2 (25.0%) | 0.019 | 0.079 |
IE, infective endocarditis; CA, community-acquired; HAIE, healthcare-associated infective endocarditis; NNHCA, non-nosocomial healthcare-associated; IQR, interquartile range; CNS, central nervous system.
Figure 2The distribution of causative pathogens in positive cultures classified according to site of infection acquisition. IE, infective endocarditis; CA, community-acquired; NNHCA, non-nosocomial healthcare-associated
Etiologic agents among patients with infective endocarditis
| HAIE | |||||||
|---|---|---|---|---|---|---|---|
| Total | Nosocomial IE | NNHCA-IE | |||||
| All
| CA-IE
| ||||||
| 46 (29.9%) | 36 (28.6%) | 10 (35.7%) | 4 (50.0%) | 6 (30.0%) | 0.455 | 0.896 | |
| 49 (44.5%) | 46 (51.1%) | 3 (16.7%) | 0 (0.0%) | 3 (21.4%) | 0.007 | 0.038 | |
| VGS | 38 (77.6%) | 36 (78.3%) | 2 (11.1%) | 0 (0.0%) | 2 (66.7%) | 0.019 | 0.542 |
| 3 (6.1%) | 3 (6.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | – | |
| Others | 8 (16.3%) | 7 (15.2%) | 1 (3.6%) | 0 (0.0%) | 1 (33.3%) | – | – |
| 33 (30.0%) | 27 (30.0%) | 6 (33.3%) | 2 (50.0%) | 4 (28.6%) | 0.779 | >0.999 | |
| | 19 (57.8%) | 16 (59.3%) | 3 (10.7%) | 0 (0.0%) | 3 (75.0%) | – | – |
| MRSA | 3 (15.8%) | 3 (18.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – | – |
| MRCNS | 4 (28.6%) | 3 (27.3%) | 1 (5.6%) | 1 (50.0%) | 0 (0.0%) | – | – |
| 28 (25.5%) | 19 (21.1%) | 9 (50.0%) | 2 (50.0%) | 7 (50.0%) | 0.017 | 0.041 | |
| Gram-negative bacilli | 8 (7.4%) | 6 (4.8%) | 2 (7.1%) | 1 (12.5%) | 1 (5.0%) | 0.638 | >0.999 |
| Enterococci | 12 (11.1%) | 9 (7.1%) | 3 (10.7%) | 1 (12.5%) | 2 (10.0%) | 0.458 | 0.628 |
| | 2 (1.9%) | 0 (0.0%) | 2 (11.1%) | 0 (0.0%) | 2 (10.0%) | – | – |
IE, infective endocarditis; CA, community-acquired; HAIE, healthcare-associated IE; NNHCA, non-nosocomial healthcare-associated; VGS, viridans group streptococci; MRSA, methicillin-resistant S. aureus; CNS, coagulase-negative staphylococci; MRCNS, methicillin-resistant CNS.
Proportion was based on patients with streptococci.
Proportion was based on patients with staphylococci.
Proportion was based on patients with S. aureus and CNS, respectively.
Includes gram-negative bacilli, enterococci, C. albicans, gram-positive bacilli, Rhodococcus, S. paucimobilis, and A. viridans.
Risk factors for in-hospital death in patients with infective endocarditis
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Risk factors | OR (95% CI) | OR (95% CI) | ||
| Age ≥60 years old | 0.966 | 1.0 (0.2–5.1) | – | – |
| Male | 0.795 | 0.8 (0.2–3.4) | – | – |
| Smoking | 0.379 | 0.4 (0.0–3.2) | – | – |
| Community-acquired IE | 0.036 | 1 | 0.041 | – |
| Nosocomial IE | 0.026 | 8.1 (1.3–50.5) | 0.050 | 8.3 (1.0–69.0) |
| NNHCA-IE | 0.061 | 4.3 (0.9–19.5) | 0.034 | 6.5 (1.2–36.3) |
| Charlson comorbidity index ≥2 | 0.922 | 1.1 (0.2–5.4) | – | – |
| Predisposing cardiac conditions | 0.785 | 0.8 (0.2–3.1) | – | – |
| Prosthetic valve | 0.817 | 0.8 (0.1–6.5) | – | – |
| Congenital heart disease | 0.422 | 0.4 (0.1–3.5) | – | – |
| WBC> 10 × 109/L | 0.035 | 4.1 (1.1–15.5) | – | – |
| Serum creatinine levels>110 (μmol/L) | 0.225 | 2.8 (0.5–15.0) | – | – |
| Albumin levels (g/L) | 0.003 | 0.8 (0.7–0.9) | 0.04 | 0.8 (0.7–0.9) |
| Urine occult blood ≥3+ | 0.017 | 5.0 (1.3–19.0) | – | – |
| Mitral valve | 0.123 | 3.5 (0.7–17.0) | – | – |
| Aortic valve | 0.263 | 0.4 (0.1–2.0) | – | – |
| Vegetation | 0.500 | 0.6 (0.1–2.9) | – | – |
| Negative blood culture | 0.473 | 1.6 (0.4–6.0) | – | – |
| Streptococcus infection | 0.180 | 0.2 (0.0–2.0) | – | – |
| Staphylococcus infection | 0.130 | 1.9 (0.8–4.5) | – | – |
OR, odds ratio; CI, confidence interval; IE, infective endocarditis; NNHCA, non-nosocomial healthcare-associated; WBC, white blood cell.
Analysis was based on 108 positive cultures.